The second axis of topical pain management therapeutics segmentation is type, which groups products by active pharmaceutical ingredient and delivery technology. NSAID‑based formulations, such as diclofenac and ibuprofen gels, dominate with an estimated 40 % share, reflecting their broad indication base across musculoskeletal disorders and established safety profile. Capsaicin preparations, ranging from low‑dose creams to high‑dose 8 % patches, account for roughly 20 % of the market; their mechanism of TRPV1 desensitization positions them as preferred options for neuropathic pain where systemic NSAIDs are less effective. Lidocaine patches, delivering 5 % local anesthetic, contribute about 15 % and are widely adopted for post‑operative and peripheral nerve pain due to rapid onset and minimal systemic absorption. Emerging cannabinoid topicals, primarily containing cannabidiol, have captured an estimated 10 % share, driven by consumer demand for plant‑derived analgesics and favorable regulatory trends. Combination products that integrate NSAIDs with lidocaine or capsaicin represent the remaining 15 %, offering synergistic pain relief and supporting adherence through simplified dosing regimens. Collectively, these type categories shape formulation pipelines and influence pricing dynamics across the market.
